Adverum Biotechnologies Inc (ADVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -143,862 | -96,210 | -47,019 | -130,927 | -89,996 |
| Depreciation Amortization | 1,139 | 690 | 247 | 1,746 | 1,550 |
| Accounts payable and accrued liabilities | 10,842 | 3,103 | 218 | -262 | 187 |
| Other Working Capital | 24,352 | 7,705 | 215 | 911 | 3,329 |
| Other Operating Activity | -2,124 | 3,174 | 3,568 | 36,070 | 20,717 |
| Operating Cash Flow | $-109,653 | $-81,538 | $-42,771 | $-92,462 | $-64,213 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 65,524 | 63,524 | 31,500 | -41,501 | -37,373 |
| PPE Investments | -482 | -340 | -220 | -388 | -327 |
| Investing Cash Flow | $65,042 | $63,184 | $31,280 | $-41,889 | $-37,700 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 10,019 | 120 | N/A | 120,003 | 119,764 |
| Financing Cash Flow | $10,019 | $120 | $N/A | $120,003 | $119,764 |
| Beginning Cash Position | 62,628 | 62,628 | 62,628 | 76,976 | 76,976 |
| End Cash Position | 28,036 | 44,394 | 51,137 | 62,628 | 94,827 |
| Net Cash Flow | $-34,592 | $-18,234 | $-11,491 | $-14,348 | $17,851 |
| Free Cash Flow | |||||
| Operating Cash Flow | -109,653 | -81,538 | -42,771 | -92,462 | -64,213 |
| Capital Expenditure | -482 | -340 | -220 | -388 | -327 |
| Free Cash Flow | -110,135 | -81,878 | -42,991 | -92,850 | -64,540 |